Arcellx reports Q3 EPS ($2.12), consensus (89c)

As of September 30 Arcellx had cash, cash equivalents, and marketable securities of $280.8M, which is anticipated to fund its operations for at least the next 12 months. "Helping patients is at the core of everything we do at Arcellx," said Rami Elghandour, Arcellx’s Chairman and CEO. "To that end, we made significant progress advancing our lead program, CART-ddBCMA for the treatment of relapsed or refractory multiple myeloma with the initiation of our iMMagine-1 pivotal study. Following the submission of IND amendments for the technical transfer of our cell and vector manufacturing, we have begun to operationally scale by initiating clinical sites, enrolling patients and dosing our first patients from Lonza, our pivotal cell manufacturer. We are currently manufacturing cells with Oxford vector at Lonza and plan to dose patients with our pivotal drug product by the end of the year. Additionally, we look forward to presenting longer-term patient data from our Phase 1 CART-ddBCMA expansion trial at the 64th ASH Annual Meeting. We continue to plan to initiate our Phase 1 ARC-SparX clinical trial of ACLX-002 in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome by year end. We’re continuing to build our organization, attracting exceptional talent and fostering a diverse and collaborative culture, allowing us to deliver on the incredible promise of our technology and company. I’m incredibly proud of our team who’ve driven these remarkable results and who make Arcellx a special place to be."